Clinical Trials Directory

A Multicenter, Phase II, Randomized, Blinded, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Sutent With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer

This is a Phase II, multicenter, randomized, blinded, placebo-controlled study designed to evaluate the safety and efficacy of combining bevacizumab with sunitinib relative to placebo with sunitinib in patients with metastatic RCC who have not received prior systemic therapy for metastatic disease. The study will enroll approximately 100 patients at approximately 20 centers in the United States.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : sunitinib
  • drug : Bevacizumab
  • drug : placebo

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Signed Informed Consent Form - Histologically confirmed metastatic RCC - Measurable disease, as defined by RECIST - Age ? 18 years - ECOG performance status of 0 or 1 - Prior nephrectomy - Ability and capacity to comply with study and follow-up procedures

External Links

Explore related trials

Contact information

Primary Contact:

Denise Haas 6507361252

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: